Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

AstraZeneca Pharma India Ltd., a mid-cap company with a market cap of Rs. 6,822 crore, has declared dividend for the fiscal year 2021–2022

This Pharma Company Declares 400% Final Dividend, Finalises Record Date

In the pharmaceutical industry, AstraZeneca Pharma India Ltd. is a mid-cap company with a market cap of Rs. 6,822 crore.

Mid-cap debt-free pharma stock finalizes record date for 400% dividend

AstraZeneca Pharma, Dr Lal Pathlabs, Torrent Pharma, and InterGlobe Aviation among those who moved the most

Movers & Shakers: 10 stocks that moved the most last week

AstraZeneca Pharma India declined 0.58% to Rs 2684, extending its losing run to seventh consecutive trading session.

AstraZeneca Pharma India hits 52-week low

AstraZeneca Pharma posted a 45.7% fall in net profit to Rs 11.42 crore in Q3 FY22 from Rs 21.05 crore posted in Q3 FY21.

AstraZeneca Pharma Q3 PAT falls 45% YoY to Rs 11 cr

Stocks to Watch: Shares of firms like Bharti Airtel, Astrazeneca Pharma, IRCTC, Escorts, Glenmark Life Sciences, Godrej Consumer Products will be in focus as they will announce their Q3 results Today’s biggest stock Gainers Market News at news18.com

Stocks to Watch Today: Adani Wilmar, Bharti Airtel, IRCTC, and Others

Astrazeneca Pharma India Ltd registered volume of 1.93 lakh shares by 14:19 IST on NSE, a 16.61 fold spurt over two-week average daily volume of 11650 shares

Volumes spurt at Astrazeneca Pharma India Ltd counter

Astra Zeneca reported NPMs of 6.04% in Sep-21 quarter compared to 12.57% in the Sep-20 quarter and 5.84% in the Jun-21 quarter.

AstraZeneca Pharma Q2 PAT lower at Rs11.95cr

The company had posted a net profit of Rs 26.33 crore for the corresponding period of the previous financial year, it said in a filing to the BSE.

AstraZeneca Pharma India Q2 Net Profit Declines 55% To Rs 12 Crore

The drug firm on Tuesday reported a 54.65 per cent decline in its net profit

AstraZeneca Pharma India Q2 net profit declines 55% to Rs 12 crore

These companies belong to sectors such as pharma, auto, and power among others.

M&M, Bosch, Power Grid, AstraZeneca Pharma among key earnings to watch today

AstraZeneca Pharma India Limited is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for core areas of healthcare.

Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

This Pharma Company Declares 400% Final Dividend, Finalises Record Date

Mid-cap debt-free pharma stock finalizes record date for 400% dividend

Movers & Shakers: 10 stocks that moved the most last week

AstraZeneca Pharma India hits 52-week low

AstraZeneca Pharma Q3 PAT falls 45% YoY to Rs 11 cr

Stocks to Watch Today: Adani Wilmar, Bharti Airtel, IRCTC, and Others

Volumes spurt at Astrazeneca Pharma India Ltd counter

AstraZeneca Pharma Q2 PAT lower at Rs11.95cr

AstraZeneca Pharma India Q2 Net Profit Declines 55% To Rs 12 Crore

Astrazeneca Pharma India Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

This Pharma Company Declares 400% Final Dividend, Finalises Record Date

Mid-cap debt-free pharma stock finalizes record date for 400% dividend

Movers & Shakers: 10 stocks that moved the most last week

AstraZeneca Pharma India hits 52-week low

AstraZeneca Pharma Q3 PAT falls 45% YoY to Rs 11 cr

Stocks to Watch Today: Adani Wilmar, Bharti Airtel, IRCTC, and Others

Volumes spurt at Astrazeneca Pharma India Ltd counter

AstraZeneca Pharma Q2 PAT lower at Rs11.95cr

AstraZeneca Pharma India Q2 Net Profit Declines 55% To Rs 12 Crore

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock